Could a vaccine keep triple negative breast cancer from returning?
NCT ID NCT05455658
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a DNA-based vaccine called STEMVAC in 33 people with early-stage triple negative breast cancer (stages IB-III). The vaccine is designed to train the immune system to recognize and attack cancer cells that express certain proteins. Participants also receive an immune booster (sargramostim). The main goal is to see if the vaccine triggers a strong immune response, not yet to measure cancer recurrence.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STEMVAC (a DNA plasmid vaccine) and sargramostim (an immune booster)
What this could lead to
If successful, this could lead to a vaccine that helps prevent triple negative breast cancer from coming back after initial treatment.
What could go wrong
This is a small, early-phase trial (33 people) focused on immune response, not yet on preventing recurrence. The vaccine may not produce a strong enough immune reaction or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21287, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States